Jeremy Gowler

Jeremy Gowler is a seasoned leader in the vaccines and pharmaceutical industry, currently serving as the Chief Executive Officer of Ophirex. With a career spanning over two decades, he has held pivotal roles in global organizations, driving innovation, commercialization, and strategic growth.

Jeremy began his career in 2002 as a sales representative at Novartis, where he quickly advanced through leadership positions across marketing, sales, medical affairs, and operations. His tenure took him across Canada, the U.S., and Switzerland, shaping his expertise in global pharmaceutical and vaccine markets.

In 2014, he transitioned to the biotechnology sector, joining PaxVax, a private equity-backed company specializing in specialty human vaccines. As VP, Global Commercial, he played a key role in the company’s success by building out the commercial organization, leading to its acquisition by Emergent BioSolutions in 2018, where he continued as VP of Global Commercial for the vaccines business unit.

Jeremy’s impact extended further when he joined Sandoz in 2020 as Global Head of Commercial for its biopharmaceutical division, spearheading commercial strategies in the rapidly evolving biosimilars market. In 2022, he took on the role of Chief Operating and Commercial Officer at Invivyd, before stepping into his current role at Ophirex in 2024.

A strong believer in the intersection of science and business, Jeremy holds a B.Sc. in Biology and Environmental Studies from the University of Victoria and a Dip.Tech. in Marketing Management from the British Columbia Institute of Technology.

Now based in California with his family, Jeremy continues to drive forward innovations that make a lasting impact on global health.